Programme

Time	Title	Speakers
13.30 - 14.15	JOINT SESSION - ENGAGING WITH BEHAVIOURAL CHOICE IN CLINICAL PRACTICE	CHAIR: CHRISTINA BURGESS
13.30 - 13.40	PSYCHOSOCIAL PROFESSIONALS: SUPPORTING MOTIVATIONAL INTERVIEWING	Gloria Rooney
13.40 - 13.50	PHYSIOTHERAPIST: SUPPORTING PHYSICAL ACTIVITY AND REHABILITATION	Johan Blokzijl
13.50 - 14.00	NURSE: SUPPORTING AUTONOMOUS CHOICES IN HEALTHY LIVING	Helen Manson
14.00 - 14.15	PANEL DISCUSSION
14.15 - 14.30	BREAK

Time	Title	Speakers
14.00 - 15.00	SESSION 4 – GENE THERAPY	CHAIR: WOLFGANG MIESBACH
14.00 - 14.15	Current status – Efficacy and safety	Paul Batty
14.15 - 14.30	Liver disease In haemophilia and impact on gene therapy	Heiner Wedemeyer
14.30 - 14.45	Future prospects for non-AAV gene and cell therapy	Thierry Vandendriessche
14.45 - 15.00	LIVE Q&A
15.00 - 15.15	BREAK
15.15 - 16.15	SESSION 5 - VON WILLEBRAND DISEASE	CHAIR: FARIBA BAGHAEI
15.15 - 15.30	Women health in von Willebrand disease	Riitta Lassila
15.30 - 15.45	Prophylaxis in von Willebrand disease – How and Who?	Eugenia Biguzzi
15.45 - 16.00	Acquired von Willebrand disease	Sophie Susen
16.00 - 16.15	LIVE Q&A
16.15 - 16.30	BREAK
16.30 - 17.30	SESSION 6 – DELIVERY OF CARE	CHAIR: ANA BOBAN
16.30 - 16.45	European adoption of the von Willebrand disease guidelines	Frank Leebeek
16.45 - 17.00	European accreditation of haemophilia and gene therapy centres	Ana Boban
17.00 - 17.15	EUHASS Update	Michael Makris
17.15 - 17.30	LIVE Q&A
17.30 - 18.00	BREAK
18.00 - 19.00	SATELLITE SYMPOSIA 7, 8, 9
19.00 - 19.15	BREAK
19.15 - 19.30	RECAP OF THE DAY – THURSDAY	CHAIR: FLORA PEYVANDI

Time	Title	Speakers
14.00 - 15.00	SESSION 7 - SLAM	CHAIR: ROBERT KLAMROTH
14.00 - 14.07	IDENTIFYING PERSONS WITH HAEMOPHILIA AT RISK FOR FUNCTIONAL DECLINE	Johan Blokzijl
14.07 - 14.14	SELECTION OF IMMUNO-DOMINANT T CELL EPITOPES FROM THE REPERTOIRE OF FVIII DERIVED PEPTIDES PRESENTED ON MHC CLASS II	Mariarosaria Miranda
14.14 - 14.21	LIVER-RELATED COMPLICATIONS DURING LONG-TERM HEPATITIS C VIRUS INFECTION AND AFTER SUCCESSFUL ANTIVIRAL TREATMENT IN PEOPLE WITH INHERITED BLEEDING DISORDERS	Cas Isfordink
14.21 - 14.28	HMB-001 - A NOVEL BISPECIFIC ANTIBODY WITH POTENTIAL FOR SUBCUTANEOUS PROPHYLACTIC TREATMENT OF MULTIPLE BLEEDING DISORDERS - INITIAL FOCUS ON GLANZMANN THROMBASTHENIA (GT)	Prafull Gandhi
14.28 - 14.35	MOST AFFECTED JOINTS IN PATIENTS WITH HAEMOPHILIA – WHAT HAS CHANGED AFTER 20 YEARS IN GERMANY?	Jamil Hmida
14.35 - 14.42	POSTPARTUM HEMORRHAGE IN PATIENTS WITH RARE BLEEDING DISORDERS IN THE NETHERLANDS: REAL-LIFE DATA FROM THE RBIN STUDY	Dominique Maas
14.42 - 15.00	LIVE Q&A
15.00 - 15.15	BREAK
15.15 - 15.45	SESSION 8 - AROSENIUS LECTURE	CHAIR: MARÍA TERESA ALVAREZ-ROMÁN
15.15 - 15.45	WHAT IS THE "TRUE" RATE OF INHIBITOR DEVELOPMENT IN HAEMOPHILIA?	Rolf Ljung
15.45 - 16.05	SESSION 9 - EAHAD SUPPORTED RESEARCH	CHAIR: KARIN FIJN VAN DRAAT
15.45 - 15.55	"DEVELOPMENT OF A NOVEL GENE THERAPY APPROACH FOR GLANZMANN THROMBASTHENIA (GT): ASSESSMENT IN CRISPR GT CELL MODEL, GT PATIENT PROGENITOR CELLS, AND NBSGW IMMUNODEFICIENT MICE" - 2020 RESEARCH GRANT PROJECT REPORT	Jose Rivera
15.55 - 16.05	“GETTING GRIP ON TOLERANCE: THE ROLE OF FC GAMMA RECEPTORS IN  IMMUNE TOLERANCE TO PROTEIN THERAPEUTICS” - THE IMPACT OF COVID-19 ON RESEARCH	Ilja Oomen
16.05 - 16.20	BREAK
16.20 - 17.45	SESSION 10 - LATEST CLINICAL TRIAL RESULTS	CHAIR: FLORA PEYVANDI
16.20 - 16.30	FINAL ANALYSIS FROM THE PIVOTAL PHASE 3 HOPE-B GENE THERAPY TRIAL: STABLE STEADY-STATE EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B	Wolfgang Miesbach
16.30 - 16.40	FITUSIRAN, AN INVESTIGATIONAL siRNA THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HAEMOPHILIA: FIRST RESULTS FROM A PHASE 3 STUDY TO EVALUATE EFFICACY AND SAFETY IN PEOPLE WITH HAEMOPHILIA A OR B WITHOUT INHIBITORS (ATLAS-A/B)	Robert Klamroth
16.40 - 16.50	SerpinPC IS WELL-TOLERATED AND REDUCES BLEEDING IN PERSONS WITH SEVERE HAEMOPHILIA (PWH) IN A 24 WEEK REPEAT DOSE STUDY - AP-0101 - Ph2a	Trevor Baglin
16.50 - 17.00	CASES OF DECREASED FVIII ACTIVITY (FVIII:C) IN PREVIOUSLY TREATED PATIENTS (PTP) DURING POST-MARKETING SURVEILLANCE OF N8-GP	Johannes Oldenburg
17.00 - 17.10	EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH MILD OR MODERATE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: RESULTS FROM THE INTERIM ANALYSIS OF THE HAVEN 6 STUDY	Johannes Oldenburg
17.10 - 17.20	EFFICACY AND SAFETY OF VALOCTOCOGENE ROXAPARVOVEC GENE TRANSFER FOR SEVERE HEMOPHILIA A: RESULTS FROM THE GENER8-1 TWO-YEAR ANALYSIS	Johnny Mahlangu
17.20 - 17.45	LIVE Q&A
17.45 - 18.00	BREAK
18.00 - 19.00	SATELLITE SYMPOSIA 10
19.00 - 19.15	BREAK
19.15 -  19:30	RECAP OF THE DAY – FRIDAY	CHAIR: MIKE MAKRIS
CLOSING REMARKS			FLORA PEYVANDI ROBERT KLAMROTH MIKE MAKRIS